www.hivandhepatitis.com

EASL 2016: International Liver Congress Underway this Week in Barcelona

The European Association for the Study of the Liver's International Liver Congress (EASL 2016) takes place April 13-17 at Fira de Barcelona. The Congress is one of the key annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at Aidsmap will be providing on-site coverage starting Thursday, April 14.

The development of interferon-free direct-acting antiviral regimens that can cure more than 90% of patients has brought about a revolution in hepatitis C treatment. Now that several of these drugs are approved, the focus has shifted to optimizing therapy for difficult-to-treat patients and ensuring access for everyone who could benefit from treatment.

This year's meeting will feature new data on Gilead Sciences' sofosbuvir/velpatasvir combination alone and with a third drug, AbbVie's pipeline candidates ABT-493 and ABT-530, and Merck's new grazoprevir/elbasvir coformulation (Zepatier). Other topics include new therapies for hepatitis B, non-alcoholic fatty liver disease, and management of liver complications including cirrhosis, liver cancer, and liver transplantation.

Look for breaking news coverage via @HIVandHepatitis on Twitter and reports at www.HIVandHepatitis.com. Abstracts, webcasts, and other conference content will be available on the International Liver Congress website as it is released from embargo.

4/13/16

Source

EASL. International Liver Congress.http://ilc-congress.eu.